Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment

Pancreatic cancer subtypes: a roadmap for precision medicine

(2018) Carolina Torres et al.   ANNALS OF MEDICINE

Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival in patients with unresectable pancreatic cancer

(2018) Makoto Nishimura et al.   GASTROINTESTINAL ENDOSCOPY

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

(2018) David Adams et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current Advances in Aptamers for Cancer Diagnosis and Therapy

(2018) Shin-ichiro Hori et al.   Cancers

Apoptosis induction activity and molecular docking studies of survivin siRNA carried by Fe 3 O 4 -PEG-LAC-chitosan-PEI nanoparticles in MCF-7 human breast cancer cells

(2017) Sanam Arami et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

A Randomized, Double‐Blinded, Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial

(2017) Andrew H. Ko et al.   ONCOLOGIST

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

(2017) Sarah J. Ross et al.   Science Translational Medicine

RNA-targeted therapeutics in cancer clinical trials: Current status and future directions

(2016) Pedro Barata et al.   CANCER TREATMENT REVIEWS

Novel cell-penetrating peptide-loaded nanobubbles synergized with ultrasound irradiation enhance EGFR siRNA delivery for triple negative Breast cancer therapy

(2016) Hui Jing et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

A phase Ib/IIa study of combination therapy with gemcitabine and Atu027 in patients with locally advanced or metastatic pancreatic adenocarcinoma.

(2016) Beate Schultheis et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1 Clinical Study of siRNA Targeting Carbohydrate Sulphotransferase 15 in Crohn’s Disease Patients with Active Mucosal Lesions

(2016) Kenji Suzuki et al.   Journal of Crohns & Colitis

Eteplirsen Approved for Duchenne Muscular Dystrophy: The FDA Faces a Difficult Choice

(2016) Cy A Stein   MOLECULAR THERAPY

Systemic Administration of Small Interfering RNA Targeting Human Nestin Inhibits Pancreatic Cancer Cell Proliferation and Metastasis

(2016) Yoko Matsuda et al.   PANCREAS

Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy

(2016) Yuval Ramot et al.   TOXICOLOGIC PATHOLOGY

Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection

(2016) Ferga C. Gleeson et al.   Oncotarget

Delivery of oligonucleotides with lipid nanoparticles

(2015) Yuhua Wang et al.   ADVANCED DRUG DELIVERY REVIEWS

Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides

(2015) Richard S. Geary et al.   ADVANCED DRUG DELIVERY REVIEWS

Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer

(2015) Tingjie Yin et al.   BIOMATERIALS

Cell-penetrating peptide-siRNA conjugate loaded YSA-modified nanobubbles for ultrasound triggered siRNA delivery

(2015) Xiangyang Xie et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

Multistep, effective drug distribution within solid tumors

(2015) Amotz Shemi et al.   Oncotarget

RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients

(2015) Talia Golan et al.   Oncotarget

Restoration of chemosensitivity by multifunctional micelles mediated by P-gp siRNA to reverse MDR

(2014) Jie Shen et al.   BIOMATERIALS

Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing

(2014) Jayaprakash K. Nair et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity

(2014) Sherry Y. Wu et al.   Nature Communications

Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic

(2014) Pedro M. D. Moreno et al.   Frontiers in Chemistry

Phase I Trial of AEG35156 an Antisense Oligonucleotide to XIAP Plus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

(2012) Daruka Mahadevan et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy

(2012) Shunrong Ji et al.   CANCER BIOLOGY & THERAPY

Clinical pharmacokinetics of second generation antisense oligonucleotides

(2012) Rosie Z Yu et al.   Expert Opinion on Drug Metabolism & Toxicology

Cellular Dynamics of RNA Modification

(2011) Chengqi Yi et al.   ACCOUNTS OF CHEMICAL RESEARCH

The Antisense Oligonucleotide Trabedersen (AP 12009) for the Targeted Inhibition of TGF-β2

(2011) Frank Jaschinski et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model

(2010) Y. Hua et al.   GENES & DEVELOPMENT

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

(2010) Frederick J Raal et al.   LANCET

Aptamers as therapeutics

(2010) Anthony D. Keefe et al.   NATURE REVIEWS DRUG DISCOVERY

Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA

(2009) Elias Fattal et al.   BRITISH JOURNAL OF PHARMACOLOGY

Aptamers: a new class of oligonucleotides in the drug discovery pipeline?

(2009) Eric Dausse et al.   CURRENT OPINION IN PHARMACOLOGY